By Gabriel Paijo 
In a significant advancement for oncology, researchers at the NCI-Designated Cancer Center at Sanford Burnham Prebys have uncovered a mechanism that allows pancreatic cancer to shield itself from the immune system and medical intervention. According to findings published on July 24, 2025, in the journal Cancer Cell, the study reveals that by blocking a cellular scavenging process known as macropinocytosis, scientists can effectively "reprogram" the environment surrounding a tumor, making it more susceptible to chemotherapy and immunotherapy. This breakthrough offers a potential new roadmap for treating pancreatic ductal adenocarcinoma (PDAC), one of the most lethal forms of human cancer.
The Ecosystem of the Tumor Microenvironment
For decades, cancer research focused primarily on the mutations within the cancer cells themselves. However, modern oncology increasingly views tumors not as isolated entities, but as complex ecosystems. Much like a city depends on its infrastructure, tumors rely on a surrounding "neighborhood" known as the tumor microenvironment (TME). This TME consists of immune cells, blood vessels, connective tissue, and the extracellular matrix—a dense network of proteins and carbohydrates that provides structural support.
In the case of pancreatic cancer, this environment is notoriously hostile to treatment. PDAC is characterized by a "desmoplastic reaction," where the tumor triggers the overproduction of dense, fibrous connective tissue. This creates a high-pressure, oxygen-poor fortress that physically blocks chemotherapy drugs from reaching their target and prevents immune cells, such as T cells, from infiltrating and attacking the malignancy.
The study from Sanford Burnham Prebys highlights how cancer cells actively manipulate this neighborhood to secure resources. To fuel their rapid and unchecked growth, PDAC cells engage in macropinocytosis—a process akin to a "fishing trawler" deploying nets to scoop up nutrients from the extracellular matrix. This scrounging behavior not only feeds the tumor but also contributes to the physical hardening of the surrounding tissue.
Deciphering the Role of Cancer-Associated Fibroblasts
Central to this discovery are fibroblasts, the cells responsible for creating connective tissue. In a healthy organ, fibroblasts maintain structural integrity and assist in wound healing. However, when a tumor is present, it "coerces" these cells into becoming cancer-associated fibroblasts (CAFs). These CAFs become the architects of the tumor’s defense, producing the collagen and metabolites that support the cancer’s survival.
Dr. Yijuan Zhang, a staff scientist at Sanford Burnham Prebys and the study’s lead author, noted that CAFs are essential collaborators in tumor progression. They provide the growth signals and metabolic fuel the cancer needs to thrive. The research team discovered that these CAFs, much like the cancer cells they support, utilize macropinocytosis to survive in the nutrient-depleted environment of the pancreas.
The pancreas is an exceptionally low-glutamine environment. Because PDAC cells consume vast amounts of glutamine—an amino acid vital for protein synthesis—the surrounding CAFs are often starved of this resource. To compensate, CAFs use macropinocytosis to scavenge proteins from their surroundings. When the research team blocked this scavenging process, they observed a dramatic shift in the CAF population.
Reprogramming the Defense: From Myofibroblasts to Inflammatory CAFs
The study identified two primary subtypes of CAFs: myofibroblasts and inflammatory CAFs. Myofibroblasts are responsible for the stiffness and density of the tumor microenvironment, acting as the "bricks and mortar" of the tumor’s fortress. Inflammatory CAFs, conversely, are associated with different gene expressions that do not contribute as heavily to the physical density of the TME.
"Most pancreatic CAFs are myofibroblasts that promote stiffness and density, making it difficult for drugs to reach the tumor," explained Dr. Cosimo Commisso, the study’s senior author and interim director of the institute’s cancer center. "By blocking macropinocytosis, we induced a subtype reprogramming. We saw fewer myofibroblasts and an increase in inflammatory CAFs."
This shift had profound implications for the physical structure of the tumor. The researchers observed a significant reduction in collagen deposits, which effectively "softened" the tumor. This change in architecture led to "vascular expansion"—a widening of the blood vessels within the tumor—which creates a more efficient pathway for drug delivery.
Chronology of the Research and Experimental Outcomes
The investigation proceeded through a series of rigorous mouse model experiments designed to test the efficacy of blocking macropinocytosis in a living system.
- Observation Phase: The team first mapped the metabolic stress of CAFs in PDAC environments, confirming that these cells were indeed starved of glutamine and relying on scavenging.
- Intervention Phase: Using a pharmacological inhibitor known as EIPA (Ethylisopropyl amiloride), the researchers successfully blocked the macropinocytosis pathway.
- Combination Testing: Recognizing that dismantling the physical barrier is only half the battle, the team combined the scavenging inhibitor with existing treatments. They tested two primary combinations: macropinocytosis inhibition plus immunotherapy (anti-PD-1 antibodies) and macropinocytosis inhibition plus chemotherapy (gemcitabine).
The results were statistically significant. In mice treated with the combination of EIPA and anti-PD-1 antibodies, the researchers observed a marked increase in the infiltration of CD4+ and CD8+ T cells. These "killer" cells, which are usually excluded from pancreatic tumors, were able to enter the tumor and mount an immune response. This synergy suppressed tumor metastasis and significantly prolonged the survival of the subjects.
When EIPA was used as a pre-treatment before the administration of gemcitabine, the chemotherapy was far more effective. The researchers noted not only a reduction in the primary tumor size but also a decrease in micrometastases—tiny clusters of cancer cells that had spread to the lungs.
Supporting Data and Statistical Significance
The data presented in Cancer Cell underscores the critical nature of these findings. Pancreatic cancer remains the third leading cause of cancer-related deaths in the United States, despite accounting for only about 3% of all cancer cases. The five-year survival rate for PDAC remains stubbornly low, hovering around 12-13%, largely because the disease is often diagnosed at an advanced stage and is resistant to standard therapies.
The study’s data indicated that:
- Fibrosis Reduction: Collagen density was reduced by nearly 40% in models where macropinocytosis was inhibited.
- Immune Infiltration: The presence of tumor-infiltrating lymphocytes (TILs) increased three-fold in the "reprogrammed" microenvironments.
- Vascular Efficiency: Blood vessel diameter increased, leading to a measurable uptick in the concentration of chemotherapy agents found within the tumor core.
Broader Implications and Future Outlook
The implications of this research extend beyond pancreatic cancer. Many other aggressive "solid" tumors, such as certain types of lung and colon cancers, are known to utilize macropinocytosis and possess dense, fibrotic microenvironments. The strategy of "reprogramming" the TME by targeting metabolic pathways could theoretically be applied to a wide range of recalcitrant malignancies.
Industry experts and oncologists not involved in the study have reacted with cautious optimism. The transition from mouse models to human clinical trials is a notoriously difficult "valley of death" in drug development. However, the use of EIPA—a derivative of a drug already used for other medical purposes—suggests a potential path for the development of safe, human-compatible macropinocytosis inhibitors.
"We believe this is a very promising strategy to pursue for developing combination therapies," Dr. Commisso stated. The focus now shifts to identifying more specific and potent inhibitors that can be safely administered to humans.
The research also highlights a shift in how scientists think about "starving" cancer. Rather than just trying to cut off a single nutrient, this approach forces the tumor’s own support system to change its fundamental nature, turning a defensive wall into a doorway for treatment.
Conclusion
The study by Sanford Burnham Prebys provides a compelling argument for the importance of metabolic research in the fight against cancer. By understanding the "scavenging" habits of cancer-associated fibroblasts, researchers have found a way to dismantle the physical and immunological barriers that make pancreatic cancer so deadly.
As the medical community continues to seek ways to improve the dismal survival rates associated with PDAC, the ability to reshape the tumor microenvironment offers a beacon of hope. The next steps will involve refining these inhibitors and moving toward clinical trials, with the ultimate goal of turning one of the world’s most aggressive cancers into a manageable, treatable condition. This research was supported by the National Institutes of Health and the National Cancer Institute, reflecting a broad institutional commitment to solving the complexities of the tumor microenvironment.